#United States #Class Action #San Francisco #Gossamer Bio #PROSERA

Gossamer Bio Under Fire: Class Action Lawsuit Emerges Amid Trial Failures

Gossamer Bio, Inc., traded on NASDAQ under the symbol GOSS, is currently at the center of a securities class action lawsuit stemming from a controversial Phase 3 clinical trial for its experimental drug, seralutinib, which aimed to treat pulmonary arterial hypertension (PAH). The lawsuit comes in light of recent failed trial results and significant loss in stock value, estimated to be around 80%.

In February 2026, Gossamer released alarming news regarding the PROSERA trial, which suggested that the primary endpoint—the change from baseline in the six-minute-walk distance at week 24—wasn't met. This announcement triggered immediate concern among investors, many of whom had heavily invested based on prior optimistic assessments by Gossamer's executive team.

The Allegations

The complaint filed against Gossamer alleges that the company and certain executives misled investors about the trial's design and its expected outcomes. Specifically, it is claimed that Gossamer executives were aware or at least reckless regarding the inadequacies in the trial’s design, particularly in terms of patient recruitment methods and monitoring processes at trial sites.

Prior to the disappointing results, Gossamer had portrayed seralutinib as a groundbreaking treatment option, highlighting its potential for substantial financial benefits across various market segments. Their assertions about the success of related studies, particularly focusing on the exemplary performance of the Merck Phase 3 STELLAR study, only fueled investor confidence.

However, the company reportedly concealed critical information. According to the claims, patients participating in Latin America were primarily heavily-treated and showed significant improvements while on a placebo treatment, which led to misleadingly optimistic expectations regarding seralutinib’s efficacy.

When the results were finally disclosed, Gossamer's management commented that “the overall treatment effect and statistical parameters were materially diluted by an outsize placebo response.” This information was contrary to earlier statements that created a false sense of security among investors, assuring them of imminent success.

Market Reaction and Further Developments

Following the revelation of the trial failures, Gossamer’s stock plummeted, causing panic among investors. The share price fell drastically, prompting an increase in legal scrutiny as Gossamer struggled to maintain its listing on the Nasdaq Global Select Market due to failure to meet the minimum share bid requirement.

Hagens Berman, a nationally recognized shareholder rights firm, is leading the class-action litigation on behalf of the aggrieved investors, urging those who believe they were similarly misled to step forward. The firm has begun investigating Gossamer’s disclosures throughout the trial process to assess the validity of the claims against the company.

Moreover, the firm is calling for individuals with non-public information about Gossamer to assist in the ongoing investigation, potentially supporting whistleblower claims under the SEC's program, which offers monetary rewards for information leading to successful enforcement actions.

Conclusion

The unfolding situation around Gossamer Bio exemplifies the intricate balance of trust and transparency in the pharmaceutical industry. As the class-action lawsuit progresses, it will likely serve as a cautionary tale for both investors and companies in the sector. The next few months will be pivotal in determining the trajectories of not only Gossamer and its stock but also the broader implications for corporate accountability in biotech and pharmaceutical development.

For more information and updates on the case, Gossamer investors are encouraged to visit Hagens Berman’s website and consider joining the legal proceedings if they believe they have been adversely affected by Gossamer's alleged misrepresentations.